<DOC>
	<DOCNO>NCT00002196</DOCNO>
	<brief_summary>The purpose study see safe effective give CI-1012 HIV-infected patient symptoms disease . This study also examine body handle CI-1012 .</brief_summary>
	<brief_title>A Study CI-1012 HIV-Infected Patients</brief_title>
	<detailed_description>Patients receive 2 week oral CI-1012 therapy open-label study , 8 patient enter dose level study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : Serologic evidence infection HIV1 . CD4+ cell count &gt; = 200 cells/mm3 . HIV1 RNA &gt; = 10,000 copies/ml . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Viral , fungal , bacterial infection require therapy topical medication . Concurrent Medication : Excluded : Prophylactic systematic antibacterial , antifungal antiviral agent . Antiretroviral therapy . NOTE : Patient must willing remain antiretroviral therapy 1 week complete study medication . Prior Medication : Excluded : Experimental therapy &gt; = 4 week prior initiation study medication . Antiretroviral treatment 3 week prior initiation study medication . Systemic steroids anticancer agent 4 week prior initiation study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>